login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NOVO-NORDISK A/S-SPONS ADR (NVO) Stock News
USA
-
New York Stock Exchange
- NYSE:NVO -
US6701002056
-
ADR
47.63
USD
+0.03 (+0.06%)
Last: 11/21/2025, 8:04:00 PM
47.69
USD
+0.06 (+0.13%)
After Hours:
11/21/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NVO Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Chartmill
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy
21 days ago - By: Chartmill
Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health
15 hours ago - By: The Motley Fool
- Mentions:
LLY
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
a day ago - By: The Motley Fool
- Mentions:
LLY
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
2 days ago - By: Stocktwits
- Mentions:
DFAX
QLTI
Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic
2 days ago - By: Zacks Investment Research
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
3 days ago - By: Benzinga
- Mentions:
VNDA
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
3 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
VKTX
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
4 days ago - By: Zacks Investment Research
- Mentions:
VNDA
ADMA
ARQT
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
5 days ago - By: Zacks Investment Research
- Mentions:
ADMA
ARQT
VTYX
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
5 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
6 days ago - By: Benzinga
Price Over Earnings Overview: Novo Nordisk
6 days ago - By: Zacks Investment Research
- Mentions:
LLY
AMGN
VKTX
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
6 days ago - By: Investor's Business Daily
- Mentions:
LLY
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
6 days ago - By: Zacks Investment Research
- Mentions:
PFE
MRK
CDTX
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
6 days ago - By: Stocktwits
- Mentions:
LLY
Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound
6 days ago - By: Zacks Investment Research
- Mentions:
LLY
JNJ
ADVM
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
9 days ago - By: Stocktwits
- Mentions:
DFAX
NDVG
LLY
Novo Nordisk Brings Back Former CEO To Lead Board
9 days ago - By: Stocktwits
- Mentions:
SRRK
VFMO
IWMW
Why Did Scholar Rock Soar 26% Today?
9 days ago - By: Zacks Investment Research
- Mentions:
LLY
AMGN
VKTX
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Please enable JavaScript to continue using this application.